TY - JOUR
T1 - Direct-acting antiviral treatment of acute hepatitis C virus infections
AU - Misra, Suresh
AU - Dieterich, Douglas T.
AU - Saberi, Behnam
AU - Kushner, Tatyana
N1 - Funding Information:
HIV-positive MSM are also at high risk of transmission. A dynamic predictive model incorporating HCV transmission, progression, and treatment showed that increasing baseline treatment rates within 1 year of diagnosis from a baseline of 46% to targets of 60%, 80%, and 90% in HIV-positive MSM in the UK population, would reduce AHCV incidence by 15%, 25%, or 36%, respectively, when projected out to year 2025 [52]. This is supported by results from the ongoing Dutch Acute HCV in HIV Study which enrolled 1420 acutely HCV-infected HIV-positive MSM treatment of AHCV. The Netherlands unrestricted access to DAA’s for all fibrosis stages in 2015 and the study reported a 52% reduction in AHCV incidence that was attributed to rapid treatment uptake compared to the prior DAA restricted era [53]. This supports significant treatment-as-prevention benefit in treating AHCV.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/8/3
Y1 - 2018/8/3
N2 - Introduction: Hepatitis C contributes to significant morbidity and mortality worldwide. AHCV is defined as documented infection within 6 months of exposure. Treating acute hepatitis C virus (AHCV) with direct-acting antiviral agents in persons who inject drugs, HIV-positive men who have sex with men, and patients who acquire HCV nosocomially can contribute to the elimination of disease globally, preclude the morbidity and mortality of chronic disease, and prevent further transmission. Areas covered: In this review, we describe the epidemiology of AHCV, its natural history, the considerations involved in the decision of whether to treat AHCV, and the most current DAA therapy guidelines. PubMed was queried using key words and bibliographies were evaluated for relevant articles. Expert commentary: Despite the obvious benefits of AHCV treatment, clinical management is limited by the ability to identify asymptomatic cases and the absence of fully supported guidelines. However, clinical research is advancing and identifying specific regimens, decreasing treatment durations, and creating strategies to target at risk groups and screen for AHCV.
AB - Introduction: Hepatitis C contributes to significant morbidity and mortality worldwide. AHCV is defined as documented infection within 6 months of exposure. Treating acute hepatitis C virus (AHCV) with direct-acting antiviral agents in persons who inject drugs, HIV-positive men who have sex with men, and patients who acquire HCV nosocomially can contribute to the elimination of disease globally, preclude the morbidity and mortality of chronic disease, and prevent further transmission. Areas covered: In this review, we describe the epidemiology of AHCV, its natural history, the considerations involved in the decision of whether to treat AHCV, and the most current DAA therapy guidelines. PubMed was queried using key words and bibliographies were evaluated for relevant articles. Expert commentary: Despite the obvious benefits of AHCV treatment, clinical management is limited by the ability to identify asymptomatic cases and the absence of fully supported guidelines. However, clinical research is advancing and identifying specific regimens, decreasing treatment durations, and creating strategies to target at risk groups and screen for AHCV.
KW - Acute hepatitis C virus
KW - HIV
KW - direct-acting antiviral therapy
KW - sofosbuvir
UR - http://www.scopus.com/inward/record.url?scp=85051751945&partnerID=8YFLogxK
U2 - 10.1080/14787210.2018.1505502
DO - 10.1080/14787210.2018.1505502
M3 - Review article
C2 - 30067402
AN - SCOPUS:85051751945
SN - 1478-7210
VL - 16
SP - 599
EP - 610
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 8
ER -